Zdeněk Ramík, Jan Václavík, Tomáš Kvapil, Libor Jelínek, Eva Kociánová, Monika Kamasová, Klára Benešová, Jiří Jarkovský, Martin Drápela, Zdeněk Lys
{"title":"明显耐药和非耐药动脉高血压患者肾功能障碍的长期轨迹及相关风险因素。","authors":"Zdeněk Ramík, Jan Václavík, Tomáš Kvapil, Libor Jelínek, Eva Kociánová, Monika Kamasová, Klára Benešová, Jiří Jarkovský, Martin Drápela, Zdeněk Lys","doi":"10.1080/08037051.2024.2353836","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objectives:</b> Evidence suggests that renal function increasingly deteriorates in patients with apparently treatment-resistant hypertension (ATRH) in comparison with those who have non-resistant arterial hypertension (NAH). We aimed to assess the long-term decline in renal function between these patient groups and identify specific risk factors contributing to the progression of renal dysfunction. <b>Methods:</b> Data for 265 patients with ATRH and NAH in a hypertension excellence centre were retrospectively evaluated. Demographic characteristics, co-morbidities, laboratory findings, secondary causes of hypertension, medication and exposure to contrast agents were assessed. To address differences between groups, adjustment with linear mixed-effect models was used. <b>Results:</b> Data from the first 4 years of follow-up were evaluated. After adjustment for age and diabetes, which were identified as independent risk factors for renal dysfunction progression in the study cohort, the mean decrease in estimated glomerular filtration rate per year was steeper with ATRH than with NAH (-1.49 <i>vs.</i> -0.65 mL/min/1.73 m<sup>2</sup> per year; difference in slope, 0.83 mL/min/1.73 m<sup>2</sup> per year; 95% confidence interval [CI]: 0.25-1.41, <i>p</i> = 0.005). In subgroup analyses, without Holm-Bonferroni correction, the prescription of MRA indicated a faster decline in renal function in ATRH. Following correction, no specific therapeutic risk factor was associated with faster progression of renal dysfunction. <b>Conclusions:</b> Renal function declines twice as fast with ATRH compared with NAH, independently of age and diabetes. Larger studies are needed to reveal risk factors for renal dysfunction in patients with hypertension.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2353836"},"PeriodicalIF":1.8000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term trajectory of renal dysfunction and related risk factors in patients with apparently treatment-resistant and non-resistant arterial hypertension.\",\"authors\":\"Zdeněk Ramík, Jan Václavík, Tomáš Kvapil, Libor Jelínek, Eva Kociánová, Monika Kamasová, Klára Benešová, Jiří Jarkovský, Martin Drápela, Zdeněk Lys\",\"doi\":\"10.1080/08037051.2024.2353836\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objectives:</b> Evidence suggests that renal function increasingly deteriorates in patients with apparently treatment-resistant hypertension (ATRH) in comparison with those who have non-resistant arterial hypertension (NAH). We aimed to assess the long-term decline in renal function between these patient groups and identify specific risk factors contributing to the progression of renal dysfunction. <b>Methods:</b> Data for 265 patients with ATRH and NAH in a hypertension excellence centre were retrospectively evaluated. Demographic characteristics, co-morbidities, laboratory findings, secondary causes of hypertension, medication and exposure to contrast agents were assessed. To address differences between groups, adjustment with linear mixed-effect models was used. <b>Results:</b> Data from the first 4 years of follow-up were evaluated. After adjustment for age and diabetes, which were identified as independent risk factors for renal dysfunction progression in the study cohort, the mean decrease in estimated glomerular filtration rate per year was steeper with ATRH than with NAH (-1.49 <i>vs.</i> -0.65 mL/min/1.73 m<sup>2</sup> per year; difference in slope, 0.83 mL/min/1.73 m<sup>2</sup> per year; 95% confidence interval [CI]: 0.25-1.41, <i>p</i> = 0.005). In subgroup analyses, without Holm-Bonferroni correction, the prescription of MRA indicated a faster decline in renal function in ATRH. Following correction, no specific therapeutic risk factor was associated with faster progression of renal dysfunction. <b>Conclusions:</b> Renal function declines twice as fast with ATRH compared with NAH, independently of age and diabetes. Larger studies are needed to reveal risk factors for renal dysfunction in patients with hypertension.</p>\",\"PeriodicalId\":9000,\"journal\":{\"name\":\"Blood Pressure\",\"volume\":\"33 1\",\"pages\":\"2353836\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Pressure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/08037051.2024.2353836\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Pressure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08037051.2024.2353836","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/7 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:有证据表明,与非耐药性动脉高血压(NAH)患者相比,明显耐药性高血压(ATRH)患者的肾功能会日益恶化。我们旨在评估这些患者群体之间肾功能的长期衰退情况,并确定导致肾功能障碍恶化的特定风险因素。研究方法我们对一家高血压卓越中心的 265 名 ATRH 和 NAH 患者的数据进行了回顾性评估。评估了人口统计学特征、合并疾病、实验室检查结果、继发性高血压病因、药物治疗和造影剂暴露情况。针对组间差异,采用线性混合效应模型进行调整。研究结果对前 4 年的随访数据进行了评估。年龄和糖尿病被确定为研究队列中肾功能不全恶化的独立风险因素,在对年龄和糖尿病进行调整后,ATRH 患者的估计肾小球滤过率每年平均下降的幅度比 NAH 患者更大(-1.49 对 -0.65 mL/min/1.73 m2/年;斜率差异为 0.83 mL/min/1.73 m2/年;95% 置信区间 [CI]:0.25-1.41,P<0.05):0.25-1.41, p = 0.005).在未进行 Holm-Bonferroni 校正的亚组分析中,处方 MRA 表明 ATRH 患者的肾功能下降更快。经过校正后,没有任何特定的治疗风险因素与肾功能障碍的加速进展相关。结论与 NAH 相比,ATRH 的肾功能下降速度是 NAH 的两倍,与年龄和糖尿病无关。需要进行更大规模的研究,以揭示高血压患者肾功能障碍的风险因素。
Long-term trajectory of renal dysfunction and related risk factors in patients with apparently treatment-resistant and non-resistant arterial hypertension.
Objectives: Evidence suggests that renal function increasingly deteriorates in patients with apparently treatment-resistant hypertension (ATRH) in comparison with those who have non-resistant arterial hypertension (NAH). We aimed to assess the long-term decline in renal function between these patient groups and identify specific risk factors contributing to the progression of renal dysfunction. Methods: Data for 265 patients with ATRH and NAH in a hypertension excellence centre were retrospectively evaluated. Demographic characteristics, co-morbidities, laboratory findings, secondary causes of hypertension, medication and exposure to contrast agents were assessed. To address differences between groups, adjustment with linear mixed-effect models was used. Results: Data from the first 4 years of follow-up were evaluated. After adjustment for age and diabetes, which were identified as independent risk factors for renal dysfunction progression in the study cohort, the mean decrease in estimated glomerular filtration rate per year was steeper with ATRH than with NAH (-1.49 vs. -0.65 mL/min/1.73 m2 per year; difference in slope, 0.83 mL/min/1.73 m2 per year; 95% confidence interval [CI]: 0.25-1.41, p = 0.005). In subgroup analyses, without Holm-Bonferroni correction, the prescription of MRA indicated a faster decline in renal function in ATRH. Following correction, no specific therapeutic risk factor was associated with faster progression of renal dysfunction. Conclusions: Renal function declines twice as fast with ATRH compared with NAH, independently of age and diabetes. Larger studies are needed to reveal risk factors for renal dysfunction in patients with hypertension.
Blood PressureMedicine-Cardiology and Cardiovascular Medicine
CiteScore
3.20
自引率
5.60%
发文量
41
期刊介绍:
For outstanding coverage of the latest advances in hypertension research, turn to Blood Pressure, a primary source for authoritative and timely information on all aspects of hypertension research and management.
Features include:
• Physiology and pathophysiology of blood pressure regulation
• Primary and secondary hypertension
• Cerebrovascular and cardiovascular complications of hypertension
• Detection, treatment and follow-up of hypertension
• Non pharmacological and pharmacological management
• Large outcome trials in hypertension.